Phosphatidylethanol and Other Ethanol Consumption Markers
The University of Texas Health Science Center at San Antonio
80 participants
Jan 7, 2025
INTERVENTIONAL
Conditions
Summary
This study is intended to help the investigators understand how a biomarker found in the blood may be used to better identify the quantity and different patterns of alcohol use. The investigators hope that the results of this study will help identify the uses of alcohol-use markers in the blood in future alcohol prevention and treatment programs. It is hoped that the information learned from this study will benefit other people in the future. The study participants will come into the lab and will (1) consume alcohol in the lab designed to produce a peak blood alcohol concentration of 0.06% and have blood collected over 6 hours followed by abstinence for 10 days to give a small blood sample 4 times and (2) to give a small amount of blood 5 times within 28 days (naturalistic drinking) and provide answers about alcohol use.
Eligibility
Inclusion Criteria3
- are ≥ 21 years old;
- are height and weight proportionate (body mass index 18-30); and
- report drinking on \> 1 days in the last month, with at least one day equal to at least achieving \~0.06% BAC.
Exclusion Criteria7
- have significant current or predicted alcohol withdrawal symptoms (CIWA-AR scores ≥ 10);
- are currently in alcohol treatment;
- have substance use disorder (except nicotine, and/or caffeine);
- have a medical condition that would contraindicate participation (a positive urine pregnancy test, self-reported scheduled surgery or liver disease);
- are currently breast feeding;
- have a presence of a DSM-5 psychiatric disorder with symptoms of psychosis and/or delirium; or
- are unable to comprehend the informed consent process or study instructions.
Interventions
Alcohol will be administered to participants by research staff. In Phase 1, participants will consume alcohol designed to produce a targeted blood alcohol concentration (BAC) of 0.06% using the modified Widmark equation.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06747364